{"anticipatedPostingDate":"2026-06","denomUnitsSelected":"Participants","description":"Intracranial ORR: Percentage of Participants with Intracranial CR or PR per RANO-BM by BICR (with or without Pembrolizumab)","reportingStatus":"NOT_POSTED","timeFrame":"Baseline through CNS Progression or Death Up to 31 Months","title":"Intracranial ORR: Percentage of Participants With Intracranial CR or PR Per RANO-BM by BICR (With or Without Pembrolizumab)","type":"SECONDARY"}